445 related articles for article (PubMed ID: 19054015)
1. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway.
Do R; Kiss RS; Gaudet D; Engert JC
Clin Genet; 2009 Jan; 75(1):19-29. PubMed ID: 19054015
[TBL] [Abstract][Full Text] [Related]
2. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
3. K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.
Do R; Paré G; Montpetit A; Hudson TJ; Gaudet D; Engert JC
Hum Mutat; 2008 May; 29(5):689-94. PubMed ID: 18350552
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Flint OP; Masters BA; Gregg RE; Durham SK
Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
[TBL] [Abstract][Full Text] [Related]
5. Human cholesterol metabolism and therapeutic molecules.
Charlton-Menys V; Durrington PN
Exp Physiol; 2008 Jan; 93(1):27-42. PubMed ID: 18165431
[TBL] [Abstract][Full Text] [Related]
6. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
Ugawa T; Kakuta H; Moritani H; Shikama H
Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis.
Tavridou A; Kaklamanis L; Megaritis G; Kourounakis AP; Papalois A; Roukounas D; Rekka EA; Kourounakis PN; Charalambous A; Manolopoulos VG
Eur J Pharmacol; 2006 Mar; 535(1-3):34-42. PubMed ID: 16545796
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
[TBL] [Abstract][Full Text] [Related]
9. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species.
Ugawa T; Kakuta H; Moritani H; Matsuda K; Ishihara T; Yamaguchi M; Naganuma S; Iizumi Y; Shikama H
Br J Pharmacol; 2000 Sep; 131(1):63-70. PubMed ID: 10960070
[TBL] [Abstract][Full Text] [Related]
10. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
Charlton-Menys V; Durrington PN
Drugs; 2007; 67(1):11-6. PubMed ID: 17209661
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
Seiki S; Frishman WH
Cardiol Rev; 2009; 17(2):70-6. PubMed ID: 19367148
[TBL] [Abstract][Full Text] [Related]
12. Potential role of nonstatin cholesterol lowering agents.
Trapani L; Segatto M; Ascenzi P; Pallottini V
IUBMB Life; 2011 Nov; 63(11):964-71. PubMed ID: 21990243
[TBL] [Abstract][Full Text] [Related]
13. Isolation and structural determination of squalene synthase inhibitor from Prunus mume fruit.
Choi SW; Hur NY; Ahn SC; Kim DS; Lee JK; Kim DO; Park SK; Kim BY; Baik MY
J Microbiol Biotechnol; 2007 Dec; 17(12):1970-5. PubMed ID: 18167444
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors.
Ishihara T; Kakuta H; Moritani H; Ugawa T; Yanagisawa I
Bioorg Med Chem; 2004 Nov; 12(22):5899-908. PubMed ID: 15498666
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
Nishimoto T; Amano Y; Tozawa R; Ishikawa E; Imura Y; Yukimasa H; Sugiyama Y
Br J Pharmacol; 2003 Jul; 139(5):911-8. PubMed ID: 12839864
[TBL] [Abstract][Full Text] [Related]
16. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver.
Okazaki H; Tazoe F; Okazaki S; Isoo N; Tsukamoto K; Sekiya M; Yahagi N; Iizuka Y; Ohashi K; Kitamine T; Tozawa R; Inaba T; Yagyu H; Okazaki M; Shimano H; Shibata N; Arai H; Nagai RZ; Kadowaki T; Osuga J; Ishibashi S
J Lipid Res; 2006 Sep; 47(9):1950-8. PubMed ID: 16741291
[TBL] [Abstract][Full Text] [Related]
17. Squalene synthase inhibitors.
Menys VC; Durrington PN
Br J Pharmacol; 2003 Jul; 139(5):881-2. PubMed ID: 12839859
[No Abstract] [Full Text] [Related]
18. Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents.
Kourounakis AP; Katselou MG; Matralis AN; Ladopoulou EM; Bavavea E
Curr Med Chem; 2011; 18(29):4418-39. PubMed ID: 21864285
[TBL] [Abstract][Full Text] [Related]
19. Visceral obesity is associated with high levels of serum squalene.
Peltola P; Pihlajamäki J; Koutnikova H; Ruotsalainen E; Salmenniemi U; Vauhkonen I; Kainulainen S; Gylling H; Miettinen TA; Auwerx J; Laakso M
Obesity (Silver Spring); 2006 Jul; 14(7):1155-63. PubMed ID: 16899796
[TBL] [Abstract][Full Text] [Related]
20. A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor.
Kerr AG; Tam LCS; Hale AB; Cioroch M; Douglas G; Agkatsev S; Hibbitt O; Mason J; Holt-Martyn J; Bataille CJR; Wynne GM; Channon KM; Russell AJ; Wade-Martins R
J Pharmacol Exp Ther; 2017 Jun; 361(3):417-428. PubMed ID: 28360334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
